To validate this hypothesis, we analyzed patient data from the TCGA cohort segregated by tumor grade (Gleason score) and found a significant reduction in UBE2J1 expression in high-grade PCa patients compared to their low-grade counterparts (Fig. 6A), affirming the clinical relevance of UBE2J1-loss. This evidence concerns the gene UBE2J1 and neoplasm.